AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study is designed to assess if the addition of intravenous (IV) iron to 500 mcg every 3
week (Q3W) darbepoetin alfa treatment enhances response as compared to the standard practice
(oral iron or no iron administration).